Phosphorus SOS1 Inhibitor for Selective RAS-SOS1 Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SOS1 inhibitors, such as BAY-293, are limited in their ability to selectively inhibit the binding of SOS1 to RAS-family proteins, particularly in blocking RAS activation and ERK phosphorylation, which is crucial for treating RAS-related diseases.
Innovation Solution
A novel SOS1 inhibitor compound is developed, characterized by specific structural components that interfere with the RAS-SOS1 interaction, effectively inhibiting ERK phosphorylation in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current SOS1 inhibitors like BAY-293 are used, then some inhibition of RAS activation occurs, but the selectivity and potency towards SOS1: RAS-family protein binding and ERK phosphorylation inhibition is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions of the quinazoline core structure. The compound features a phosphonic acid group at position 4, specific substituents at positions 6 and 7, and a piperazine ring with specific substitutions, creating localized regions of enhanced interaction with SOS1 binding site that improve selectivity without requiring complete structural redesign
Solution Approach 2:
The patent employs composite material principles by combining multiple functional moieties into a single inhibitor molecule: a quinazoline core provides base binding affinity, a phosphonic acid group enhances SOS1 interaction, piperazine rings provide additional binding contacts and solubility, and various substituents fine-tune the interaction. This composite structure achieves high selectivity and potency that individual components cannot provide alone
2Ease of manufacture
If the inhibitor structure is simplified for easier manufacture, then manufacturing cost decreases, but the potency and selectivity of ERK phosphorylation inhibition may be compromised
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct synthetic modules: a quinazoline core that can be prepared by known methods, phosphonic acid groups that can be introduced via standardized coupling reactions, piperazine rings that can be attached through nucleophilic substitution, and various substituents that can be installed using conventional organic synthesis techniques. This modular approach enables stepwise synthesis with good overall yield while maintaining the complete pharmacophore for high potency
Solution Approach 2:
The patent utilizes parameter changes by systematically varying substituents at different positions of the quinazoline core to optimize the balance between potency and manufacturability. By adjusting the nature and position of substituents (R1-R6 groups), the synthesis route complexity can be tuned while maintaining the essential phosphonic acid-quinazoline-piperazine scaffold that provides SOS1 selectivity and ERK inhibition potency
Data Source
AI summary
The present application relates to the field of pharmaceutical chemistry, relates to an SOS1 inhibitor containing phosphorus, i.e., a compound of formula (I) and a preparation method therefor, and a pharmaceutical composition containing the compound, and relates to use thereof in the preparation of a drug for treating a disease and/or disorder related to SOS1 or regulated by SOS1.